Dr Reddys Laboratories Ltd (RDY) stock
RDYNYSEPharmaceutical PreparationsFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Score 7/30
$14.74+0.01 (+0.07%)
Close on Nov 13, 2026Market cap $12.30BP/E 26.9Yield 0.58%
Dr Reddys Laboratories EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2026 it was 51.42 INR, down 24.1% from the year before. Over ten years it grew 8.2% a year on average. The highest annual figure on record is 67.78 INR in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | 51.42 INR | -24.1% |
| FY2025 | Mar 31, 2025 | 67.78 INR | +1.5% |
| FY2024 | Mar 31, 2024 | 66.80 INR | +23.3% |
| FY2023 | Mar 31, 2023 | 54.17 INR | +91.2% |
| FY2022 | Mar 31, 2022 | 28.34 INR | +36.7% |
| FY2021 | Mar 31, 2021 | 20.73 INR | -11.7% |
| FY2020 | Mar 31, 2020 | 23.48 INR | +3.8% |
| FY2019 | Mar 31, 2019 | 22.62 INR | +91.7% |
| FY2018 | Mar 31, 2018 | 11.80 INR | -18.2% |
| FY2017 | Mar 31, 2017 | 14.42 INR | -38.4% |
| FY2016 | Mar 31, 2016 | 23.40 INR | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?